Loading clinical trials...
Loading clinical trials...
An Open Label Multi-Center Extension Study to Evaluate the Long-term Safety of Zorblisa™ (SD-101-6.0) in Patients With Epidermolysis Bullosa
Conditions
Interventions
SD-101-6.0 cream
Locations
30
United States
Phoenix, Arizona, United States
Redwood City, California, United States
Aurora, Colorado, United States
Washington D.C., District of Columbia, United States
Chicago, Illinois, United States
Minneapolis, Minnesota, United States
Start Date
June 9, 2015
Primary Completion Date
September 3, 2018
Completion Date
September 3, 2018
Last Updated
September 27, 2019
NCT06423573
NCT06330350
NCT05157958
NCT03526159
NCT07050810
NCT06330324
Lead Sponsor
Scioderm, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions